See more : Miliboo Société anonyme (ALMLB.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Seres Therapeutics, Inc. (MCRB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seres Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Public Joint Stock Company Mining and Metallurgical Company Norilsk Nickel (MNOD.IL) Income Statement Analysis – Financial Results
- Matrix Composites & Engineering Ltd (MCE.AX) Income Statement Analysis – Financial Results
- TCI Express Limited (TCIEXP.NS) Income Statement Analysis – Financial Results
- Ricoh Leasing Company, Ltd. (8566.T) Income Statement Analysis – Financial Results
- GCL New Energy Holdings Limited (SMTLD) Income Statement Analysis – Financial Results
Seres Therapeutics, Inc. (MCRB)
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 126.33M | 7.13M | 144.93M | 33.22M | 34.51M | 28.27M | 32.10M | 21.77M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 704.00K | 1.00M | 1.73M | 90.57M | 80.14M | 95.96M | 89.46M | 81.99M | 728.00K | 10.72M | 0.00 | 0.00 |
| Gross Profit | 125.62M | 6.12M | 143.20M | -57.36M | -45.64M | -67.69M | -57.36M | -60.22M | -728.00K | -10.72M | 0.00 | 0.00 |
| Gross Profit Ratio | 99.44% | 85.91% | 98.80% | -172.68% | -132.26% | -239.46% | -178.68% | -276.68% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 145.86M | 172.92M | 141.89M | 90.57M | 80.14M | 95.96M | 89.46M | 81.99M | 38.10M | 10.72M | 4.81M | 2.08M |
| General & Administrative | 87.74M | 79.69M | 69.26M | 30.78M | 24.75M | 32.60M | 34.04M | 32.62M | 16.76M | 4.36M | 1.25M | 956.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 87.74M | 79.69M | 69.26M | 30.78M | 24.75M | 32.60M | 34.04M | 32.62M | 16.76M | 4.36M | 1.25M | 956.00K |
| Other Expenses | 0.00 | 1.00M | -1.73M | 981.00K | 1.07M | 170.00K | 425.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 233.60M | 253.62M | 209.42M | 121.35M | 104.89M | 128.55M | 123.50M | 114.61M | 54.86M | 15.08M | 6.05M | 3.03M |
| Cost & Expenses | 234.31M | 253.62M | 209.42M | 121.35M | 104.89M | 128.55M | 123.50M | 114.61M | 54.86M | 15.08M | 6.05M | 3.03M |
| Interest Income | 7.30M | 3.06M | 2.87M | 946.00K | 1.03M | 0.00 | 0.00 | 2.23M | 638.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.18M | 6.02M | 2.91M | 2.92M | 502.00K | 1.17M | 1.59M | 969.00K | 555.00K | 0.00 | 42.00K | 0.00 |
| Depreciation & Amortization | 6.24M | 11.85M | 9.22M | 8.89M | 9.83M | 7.86M | 7.26M | 4.21M | 728.00K | 190.00K | 88.00K | 25.00K |
| EBITDA | -94.31M | -237.51M | -56.72M | -77.31M | -59.95M | -91.08M | -82.12M | -88.63M | -54.13M | -14.89M | -5.96M | -3.01M |
| EBITDA Ratio | -74.65% | -3,425.04% | -43.24% | -259.53% | -197.90% | -354.77% | -262.11% | -396.97% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -107.98M | -246.49M | -64.49M | -88.13M | -71.88M | -100.28M | -91.40M | -92.84M | -54.86M | -15.08M | -6.05M | -3.03M |
| Operating Income Ratio | -85.48% | -3,458.05% | -44.50% | -265.33% | -208.31% | -354.77% | -284.72% | -426.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.74M | -3.67M | -1.09M | -997.00K | 1.60M | 1.34M | 2.02M | 1.26M | 76.00K | -1.63M | -50.00K | -93.00K |
| Income Before Tax | -113.72M | -250.16M | -65.58M | -89.13M | -70.28M | -98.94M | -89.38M | -91.58M | -54.78M | -16.71M | -6.10M | -3.13M |
| Income Before Tax Ratio | -90.02% | -3,509.50% | -45.25% | -268.33% | -203.68% | -350.03% | -278.44% | -420.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.67M | -4.08M | -2.67M | -6.04M | 1.34M | -1.59M | 2.23M | -804.00K | 1.63M | 42.00K | 0.00 |
| Net Income | -113.72M | -253.82M | -61.50M | -86.45M | -64.24M | -98.94M | -89.38M | -91.58M | -54.78M | -16.71M | -6.10M | -3.13M |
| Net Income Ratio | -90.02% | -3,560.94% | -42.43% | -260.29% | -186.19% | -350.03% | -278.44% | -420.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.30 | -2.33 | -0.56 | -0.20 | -0.15 |
| EPS Diluted | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.30 | -2.33 | -0.56 | -0.20 | -0.15 |
| Weighted Avg Shares Out | 128.00M | 108.08M | 91.70M | 79.79M | 56.65M | 40.74M | 40.45M | 39.85M | 23.53M | 29.78M | 29.78M | 20.68M |
| Weighted Avg Shares Out (Dil) | 128.00M | 108.08M | 91.70M | 79.79M | 56.65M | 40.74M | 40.45M | 39.85M | 23.53M | 29.78M | 29.78M | 20.68M |
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
Seres Therapeutics' Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN
Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Seres Therapeutics: FDA Approval Straight Ahead
The Clock Is Ticking For Seres Therapeutics: I'm Not Afraid
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D.
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy
Seres Gets Closer To Good Times
Source: https://incomestatements.info
Category: Stock Reports